Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abercrombie & Fitch Co. (ANF) vs Twist Bioscience Corp (TWST) Price & Performance

Abercrombie & Fitch Co.Trade
Twist Bioscience CorpTrade

Price performance (Past 24H)

Key statistics

Abercrombie & Fitch Co. vs Twist Bioscience Corp — how do they compare? Abercrombie & Fitch Co. trades at $118.27 (market cap $5.27B), while Twist Bioscience Corp trades at $123.13 (market cap $7.82B). The key difference: Twist Bioscience Corp is the larger of the two by market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Abercrombie & Fitch Co. nearer its low. Which is the better fit depends on your goals.

ANFTWST
Market Cap
$5.27B$7.82B
Sector
Consumer CyclicalHealth
52-Week High
$129.85$124.88
52-Week Low
$65.61$24.16
Enterprise Value
$5.94B$7.75B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abercrombie & Fitch Co.

Abercrombie & Fitch (ANF) trades at $112.62, up 1.94% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with 2025 revenue of $4.95B and net income of $566.22M, achieving consistent earnings beats in recent quarters. Valuation remains attractive with P/E of 10.89 and EV/EBITDA of 6.54, while profitability metrics show impressive ROE of 39.04% and net margin of 9.34%.

ANF presents a compelling investment case with strong operational performance and reasonable valuation, though technical indicators show overbought conditions. Key risks include retail sector volatility and potential growth headwinds in EMEA markets. Analyst consensus leans neutral with 50% hold ratings, while institutional ownership trends show continued interest from major funds.

Twist Bioscience Corp

Twist Bioscience (TWST) trades at $115.67, up 6.04% in the last session, with bullish technical signals from moving averages and a recent analyst upgrade. Revenue growth is strong, with fiscal 2026 Q3 revenue up 23% year-over-year to $118.4 million, though the company remains unprofitable with negative net income margins. A recent $300 million public offering at $96 per share indicates capital raising for expansion.

The outlook is mixed: robust revenue growth and high analyst buy ratings (78.57%) support upside potential, but persistent losses, cash burn, and high valuation ratios pose significant risks. Investors should weigh growth prospects against financial sustainability concerns.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Abercrombie & Fitch Co.

Abercrombie & Fitch Co is a specialty retailer that sells casual clothing, personal-care products, and accessories for men, women, and children. It sells direct to consumer through its stores and websites, which include the Abercrombie & Fitch, Abercrombie kids, and Hollister brands. Most stores are in the United States, but the company does have many stores in Canada, Europe, and Asia. All stores are leased. Abercrombie ships to well over 100 countries via its websites. The company sources its merchandise from dozens of vendors that are primarily located in Asia and Central America. Abercrombie has two distribution centers in Ohio to support its North American operations. It uses third-party distributors for sales in Europe and Asia.

Read more on ANF

About Twist Bioscience Corp

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.

Read more on TWST